Mutated Cells & Blood Cancer Development – Study Finds

Blood Cancer’s Hidden Impact: Even Small Numbers of Cancer Cells Cause ‍Systemic Damage, Study Finds

Even ⁣low levels of cancerous cells ⁤can profoundly ⁢disrupt the body’s blood-producing system and bone health, according to a groundbreaking⁣ study published in ⁣the journal Blood from the American Society of Hematology. Researchers at Brown University ⁣have discovered that non-mutated, healthy blood-producing cells are significantly impacted by the presence of cancer cells, suggesting current ⁤treatment strategies for blood⁢ cancers may need to be re-evaluated.

The study, led by Patrycja⁤ Dubielecka, associate professor at the Warren Alpert Medical School of brown University and co-leader of the Cancer Biology Program at Brown’s Legorreta Cancer Center, revealed the⁤ extent to ⁣which mutated cancer cells alter both⁤ the blood-forming system and bone biology.

“We realized there would⁢ be some impact of introducing the⁣ cancer⁢ cells,⁢ but the ⁣extent of how profoundly‍ both the blood-forming system and bone biology have changed was absolutely stunning to see,” said ‍Dubielecka, who is also the director of translational hematology at Rhode ⁢Island Hospital.

Researchers, including lead author dennis Bonal, a postdoctoral fellow at Brown, developed a ⁢novel mouse model utilizing molecular ⁢tags to track both introduced cancer cells and the recipient cells within the ‍body. This allowed ⁢them to observe the systemic effects of cancer progress over an extended period – eight months – mirroring the gradual onset of ⁤cancer in humans.

The ‍team focused on cancer cells⁤ carrying a specific gene mutation,JAK2,and found a significant level of “molecular mimicry” occurring between the JAK2-mutated cancer cells and their healthy,non-mutated counterparts. This suggests the cancer cells are inducing‍ changes at a molecular level in surrounding healthy cells.

These findings have significant implications for the treatment of blood cancers, especially those⁢ currently managed with⁣ a “watchful waiting” approach when detected early in younger‍ patients. Currently, treatment often focuses on⁢ symptom management rather than aggressive eradication of the mutated cells.”Based on our findings, this strategy needs to be revised,”‍ Dubielecka stated. “The ⁤moment that mutated blood cancer cells are detected in the system, the effort should really be directed toward shrinking the frequency of this clone that carries the mutation – because we know that over time this clone will induce ⁢significant ‍damaging changes that will⁢ be challenging or even impossible to reverse.”

The study highlights the importance of ⁢understanding the impact of ‍cancer cells on the surrounding microenvironment ⁢and ‍the⁣ systemic consequences of even small numbers of mutated cells. Dubielecka’s team is now focusing on further investigating the molecular changes occurring within ‍these bystander, non-mutated cells to identify potential strategies for reversing the damage and improving patient outcomes.

This research was funded by the National Cancer Institute (R01CA218079) and the National Institute of General ⁢Medicine (P20GM119943,P30GM145500).